Masters of Longevity - The Pulse

Longevity Technology18 Jun 2026
AILG AI Research, D&D Pharmatech partner to design oral peptides using AI (Longevity Technology)

LG AI Research, D&D Pharmatech partner to design oral peptides using AI

Read about an industry partnership combining AI-driven peptide design with formulation expertise to advance orally deliverable peptide therapeutics.

Key takeaways
  • LG AI Research signed a master agreement with D&D Pharmatech on 17 June 2026.
  • While D&D Pharmatech will handle structural design.
  • LG AI Research will also leverage its EXAONE Discovery and other biology AI initiatives.
Frontiers - Health18 Jun 2026
AIEpicardial adipose tissue in cardiovascular diseases: a potential therapeutic target (Frontiers - Health)

Epicardial adipose tissue in cardiovascular diseases: a potential therapeutic target

A review of epicardial adipose tissue biology, imaging methods, and its potential as a therapeutic target in cardiovascular disease.

Key takeaways
  • Dyslipidemia are widely recognized risk factors for CVDs ( 2 ).
  • It is distinct from other visceral adipose tissue due to its anatomical position.
  • Nevertheless, the specific molecular pathways connecting EAT to CVDs have not yet been fully elucidated.
Nature - Main18 Jun 2026
Daily briefing: The proteins that protect us from deadly mutations (Nature - Main)

Daily briefing: The proteins that protect us from deadly mutations

A science roundup that highlights proteins buffering harmful mutations and other notable biology and policy developments.

Key takeaways
  • View all journals Sea levels and ocean temperatures reached alarming highs in Asia last year.
  • Early warning and coordinated action will be essential to save lives, says the report.
  • If nicotine were to be added to the UN Convention on Psychotropic Substances.
Frontiers - Health18 Jun 2026
AIAcupuncture is independently associated with improved recovery in Guillain–Barré syndrome: a prospective observational study (Frontiers - Health)

Acupuncture is independently associated with improved recovery in Guillain–Barré syndrome: a prospective observational study

A prospective clinical study examining complementary neurorehabilitation added to standard care for an acute immune-mediated peripheral neuropathy and short-term outcomes.

Key takeaways
  • Prospective study enrolled 128 Guillain–Barré syndrome patients allocated to two groups.
  • At two weeks, complementary treatment achieved 53.45% versus 35.71% improvement in Hughes scores.
  • Adjusted analysis showed higher odds of MRC improvement with complementary therapy, adjusted OR 3.165.